Diabetes and insulin-delivery statistics 2026
Primary, citable figures on diabetes, insulin use, device adoption, outcomes and costs. Each figure is taken from the source shown, with a direct URL and the date we accessed it.
The short answer
An estimated 589 million adults worldwide had diabetes in 2024 (ages 20–79).IDF Diabetes Atlas, 11th ed. (2025)
In 2024 an estimated 9.15 million people of all ages were living with diagnosed type 1 diabetes (IDF Diabetes Atlas 2025, section 3.8). The Atlas gives other rounded figures elsewhere (9.1 million, 9.2 million and “over 9.5 million”).
Global diabetes health expenditure was an estimated USD 1.015 trillion in 2024 (adults 20–79), and an estimated 43% of adults aged 20–79 living with diabetes (252 million) are undiagnosed.IDF Global Factsheet (2025)
In Singapore, diabetes prevalence among residents aged 18–74 was 9.1% (crude) and 8.8% (age‑standardised) in 2023–2024.MOH National Population Health Survey 2024 (report)
Among adults with type 1 diabetes in England, 50.4% were using wearable glucose monitoring devices by March 2022.NDA Type 1 overview (2021–22) Hybrid closed loop reached 62% of children and young people in 2024/25, up from 36%; the 2024/25 data are provisional.NICE reporting NPDA, 16 June 2025
How many people have diabetes
| Metric | Value | Year | Source | Accessed |
|---|---|---|---|---|
| Adults with diabetes worldwide (ages 20–79) | 589 million | 2024 | International Diabetes Federation, Diabetes Atlas 11th ed. (2025) · see also research ref 15 | 29 Oct 2026 |
| People with diagnosed type 1 diabetes worldwide (all ages) | 9.15 million | 2024 | International Diabetes Federation, Diabetes Atlas 11th ed. (2025), section 3.8. The Atlas gives other rounded figures elsewhere (9.1 million, 9.2 million and “over 9.5 million”). | 29 Oct 2026 |
| Adults with diabetes who are undiagnosed | 43% (252 million) | 2024 | International Diabetes Federation, Global Factsheet (2025) | 29 Oct 2026 |
| Singapore residents with diabetes (ages 18–74), crude | 9.1% | 2023–2024 | Ministry of Health, National Population Health Survey 2024 (Report) | 29 Oct 2026 |
| Singapore residents with diabetes (ages 18–74), age‑standardised | 8.8% | 2023–2024 | Ministry of Health, National Population Health Survey 2024 (Report) | 29 Oct 2026 |
Global figures are from the IDF Diabetes Atlas 11th edition (2025), which reports 2024 estimates. Singapore figures are from the MOH National Population Health Survey 2024 health-examination component.
Insulin use
| Metric | Value | Year | Source | Accessed |
|---|---|---|---|---|
| People with type 1 diabetes require insulin to survive (statement, not a statistic) | — | — | IDF Diabetes Atlas 11th ed. (2025), PDF page 18 (printed page 12) | 29 Oct 2026 |
| US adults aged 20+ with diagnosed diabetes: reported both type 1 diabetes and insulin use | 6.1% (1.8 million) | 2023 | CDC National Diabetes Statistics Report (updated 11 March 2026) | 29 Oct 2026 |
| US adults aged 20+ with diagnosed diabetes: started insulin within 1 year of diagnosis | 13.3% (3.8 million) | 2023 | CDC National Diabetes Statistics Report (updated 11 March 2026). CDC notes: “Validated methods to distinguish between types of diabetes in surveys are not available.” | 29 Oct 2026 |
CGM and automated insulin delivery adoption
| Metric | Value | Year | Source | Accessed |
|---|---|---|---|---|
| Adults (19+) with type 1 diabetes in England using wearable glucose monitoring devices, by March 2022 | 50.4% | 2021–22 | NHS England, National Diabetes Audit Type 1 overview | 29 Oct 2026 |
| Children and young people with type 1 diabetes in England using hybrid closed loop (provisional 2024/25; up from 36% in 2023/24) | 62% | 2024/25 | NICE reporting NPDA, 16 June 2025 | 29 Oct 2026 |
Adult hybrid-closed-loop uptake varies by country and programme and is tracked in national dashboards; where a stable primary report was not available at the time of access, we have not included a figure.
Outcomes and time-in-range from trials
- iDCL (NEJM 2019; 168 people): % time 70–180 mg/dL rose from 61% to 71% in the closed‑loop group vs 59% in the control group (sensor‑augmented pump).N Engl J Med, 2019 · research ref 46
- Omnipod 5 (Diabetes Care 2021; single‑arm): after 2 weeks of standard therapy and 3 months on the system, time in range improved by 15.6 percentage points in children (6–13.9 years) and 9.3 points in adolescents/adults (14–70 years).Diabetes Care, 2021 · research ref 47
- iLet bionic pancreas (NEJM 2022): HbA1c fell from 7.9% to 7.3% in the bionic‑pancreas group vs unchanged at 7.7% in the standard‑care group.N Engl J Med, 2022 · research ref 48
Cost and burden
| Metric | Value | Year | Source | Accessed |
|---|---|---|---|---|
| Global health expenditure on diabetes | USD 1.015 trillion (adults 20–79) | 2024 | International Diabetes Federation, Global Factsheet (2025) | 29 Oct 2026 |
| Estimated cost of diagnosed diabetes, United States (total) | USD 412.9 billion | 2022 | Diabetes Care (ADA), 2024;47(1):26–43 (PDF) | 29 Oct 2026 |
Methodology and notes
We include only figures we could verify from primary sources: government health bodies (US CDC, NHS England, NICE, Singapore Ministry of Health), the International Diabetes Federation, and peer‑reviewed journals (NEJM, Diabetes Care). Each row states the number as written by the source, the year the source reports, a direct URL and our access date. Where suitable, we cross‑link to the numbered references on the research brief.
What this page does not show. We do not include company estimates, analyst projections or marketing pages as the basis of a number. Where we could not confirm a figure from a primary source, we left it out.
Disclaimer. Micropatch is a research concept, not a medical device. This page is not medical advice. Talk to your clinician before changing any treatment.
CSV download: /data/diabetes-statistics.csv